

**Supplementary Table 1.** Baseline characteristics of second-line drugs in a subgroup with available health screening data

Variable	MET+SU (n=1,504)	MET+DPP4i (n=2,384)	MET+TZD (n=224)	P value
Age, yr	59.9±10.0	57.0±9.7	57.3±9.5	<0.001
Men, sex	736 (48.9)	1,198 (50.3)	123 (54.9)	0.234
Duration of MET treatment, mo	10.1±3.5	10.3±3.5	10.0±3.5	0.104
Duration of second line therapy, mo	20.4±16.8	20.2±16.0	19.3±16.9	0.040
Body mass index, kg/m <sup>2</sup>	25.0±3.3	24.9±3.1	24.7±3.0	0.401
Waist circumference, cm	84.9±8.5	84.2±8.4	83.6±8.1	0.012
Systolic blood pressure, mm Hg	128.6±14.7	126.1±14.5	127.2±14.8	<0.001
Total cholesterol, mg/dL	186.7±39.4	177.8±36.1	177.7±35.2	<0.001
Triglyceride, mg/dL	134.5 (98.0–189.0)	124.0 (90.0–176.0)	132.0 (92.5–187.0)	0.001
HDL-C, mg/dL	51.4±20.9	51.4±23.0	50.0±12.2	0.645
LDL-C, mg/dL	106.0±50.1	99.9±57.6	97.6±31.6	0.001
Fasting glucose, mg/dL	132.0 (115.0–152.5)	126.0 (113.0–142.0)	123.5 (112.0–142.0)	<0.001
Creatinine, mg/dL	1.01±1.01	0.98±0.99	1.04±1.07	0.528
Smoking status				0.383
Never	978 (65.0)	1,550 (65.0)	137 (61.2)	
Former	322 (21.4)	517 (21.7)	61 (27.2)	
Current	204 (13.6)	317 (13.3)	26 (11.6)	
Family history				
Stroke	125 (8.3)	262 (11.0)	24 (10.7)	0.024
Heart disease	69 (4.6)	143 (6.0)	11 (4.9)	0.157
Charlson score, unit	3.1±1.7	3.1±1.6	3.1±1.7	0.851
Intravitreal injection	13 (0.9)	20 (0.8)	0 (0.0)	0.382
Inclusion year				<0.001
2009	665 (44.2)	1,181 (49.5)	133 (59.4)	
2010	390 (25.9)	631 (26.5)	46 (20.5)	
2011	265 (17.6)	349 (14.6)	33 (14.7)	
2012	184 (12.2)	223 (9.4)	12 (5.4)	

Values are presented as mean ± standard deviation, number (%), or median (interquartile range).

MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.